Sildenafil for pediatric orbital lymphangioma

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

IMPORTANCE Orbital lymphangiomas, congenital hamartomas of the lymphovascular tissue, are often associated with significant ocular complications and can be challenging to treat. To date, therapeutic approaches have demonstrated variable results and have significant ocular and systemic risks. We present 2 cases of pediatric orbital lymphangioma that responded to treatment with oral sildenafil. OBSERVATIONS This is a report of a series of 2 patients at the University of California-Davis Medical Center treated between March 2011 and October 2012. The first patient was a 12-month-old male infant whose extensive orbital and facial lymphangioma responded to sildenafil after repeated sclerosing and drainage procedures failed to achieve remission. The second patient was a 12-year-old boy whose orbital lymphangioma and associated ocular pain improved with sildenafil, making enucleation unnecessary. CONCLUSIONS AND RELEVANCE These reported cases demonstrate promise for sildenafil as a noninvasive therapy for pediatric lymphangioma. Larger clinical trials are needed to clarify the optimal length of treatment, use as monotherapy, and long-term adverse effects.

Original languageEnglish (US)
Pages (from-to)1228-1230
Number of pages3
JournalJAMA Ophthalmology
Volume131
Issue number9
DOIs
StatePublished - Sep 2013

Fingerprint

Lymphangioma
Pediatrics
Eye Pain
Hamartoma
Therapeutics
Drainage
Sildenafil Citrate
Clinical Trials

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Sildenafil for pediatric orbital lymphangioma. / Gandhi, Nandini G; Lin, Lily Koo; O'Hara, Mary A.

In: JAMA Ophthalmology, Vol. 131, No. 9, 09.2013, p. 1228-1230.

Research output: Contribution to journalArticle

@article{eee10f96fb4e4e51b4e011400ae674f6,
title = "Sildenafil for pediatric orbital lymphangioma",
abstract = "IMPORTANCE Orbital lymphangiomas, congenital hamartomas of the lymphovascular tissue, are often associated with significant ocular complications and can be challenging to treat. To date, therapeutic approaches have demonstrated variable results and have significant ocular and systemic risks. We present 2 cases of pediatric orbital lymphangioma that responded to treatment with oral sildenafil. OBSERVATIONS This is a report of a series of 2 patients at the University of California-Davis Medical Center treated between March 2011 and October 2012. The first patient was a 12-month-old male infant whose extensive orbital and facial lymphangioma responded to sildenafil after repeated sclerosing and drainage procedures failed to achieve remission. The second patient was a 12-year-old boy whose orbital lymphangioma and associated ocular pain improved with sildenafil, making enucleation unnecessary. CONCLUSIONS AND RELEVANCE These reported cases demonstrate promise for sildenafil as a noninvasive therapy for pediatric lymphangioma. Larger clinical trials are needed to clarify the optimal length of treatment, use as monotherapy, and long-term adverse effects.",
author = "Gandhi, {Nandini G} and Lin, {Lily Koo} and O'Hara, {Mary A}",
year = "2013",
month = "9",
doi = "10.1001/jamaophthalmol.2013.4201",
language = "English (US)",
volume = "131",
pages = "1228--1230",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Sildenafil for pediatric orbital lymphangioma

AU - Gandhi, Nandini G

AU - Lin, Lily Koo

AU - O'Hara, Mary A

PY - 2013/9

Y1 - 2013/9

N2 - IMPORTANCE Orbital lymphangiomas, congenital hamartomas of the lymphovascular tissue, are often associated with significant ocular complications and can be challenging to treat. To date, therapeutic approaches have demonstrated variable results and have significant ocular and systemic risks. We present 2 cases of pediatric orbital lymphangioma that responded to treatment with oral sildenafil. OBSERVATIONS This is a report of a series of 2 patients at the University of California-Davis Medical Center treated between March 2011 and October 2012. The first patient was a 12-month-old male infant whose extensive orbital and facial lymphangioma responded to sildenafil after repeated sclerosing and drainage procedures failed to achieve remission. The second patient was a 12-year-old boy whose orbital lymphangioma and associated ocular pain improved with sildenafil, making enucleation unnecessary. CONCLUSIONS AND RELEVANCE These reported cases demonstrate promise for sildenafil as a noninvasive therapy for pediatric lymphangioma. Larger clinical trials are needed to clarify the optimal length of treatment, use as monotherapy, and long-term adverse effects.

AB - IMPORTANCE Orbital lymphangiomas, congenital hamartomas of the lymphovascular tissue, are often associated with significant ocular complications and can be challenging to treat. To date, therapeutic approaches have demonstrated variable results and have significant ocular and systemic risks. We present 2 cases of pediatric orbital lymphangioma that responded to treatment with oral sildenafil. OBSERVATIONS This is a report of a series of 2 patients at the University of California-Davis Medical Center treated between March 2011 and October 2012. The first patient was a 12-month-old male infant whose extensive orbital and facial lymphangioma responded to sildenafil after repeated sclerosing and drainage procedures failed to achieve remission. The second patient was a 12-year-old boy whose orbital lymphangioma and associated ocular pain improved with sildenafil, making enucleation unnecessary. CONCLUSIONS AND RELEVANCE These reported cases demonstrate promise for sildenafil as a noninvasive therapy for pediatric lymphangioma. Larger clinical trials are needed to clarify the optimal length of treatment, use as monotherapy, and long-term adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=84884546471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884546471&partnerID=8YFLogxK

U2 - 10.1001/jamaophthalmol.2013.4201

DO - 10.1001/jamaophthalmol.2013.4201

M3 - Article

C2 - 23828510

AN - SCOPUS:84884546471

VL - 131

SP - 1228

EP - 1230

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 9

ER -